Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Peter Clark, MA, MD, FRCP: A Payer Perspective

Opening Session Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Nov
06
Today In Oncology
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
Pediatric Brain Tumors Prognostic AI Model Guides Precision Therapy Choices
Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression
Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma
A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo